← All trials
NCT04801199
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 26, 2020
- Primary completion
- Jan 13, 2021
- Completion date
- Feb 11, 2021
- First posted
- Mar 16, 2021
- Last posted
- Aug 17, 2021
- Enrollment
- 355
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cadila HealthcareLead sponsor
- Cadila HealthcareStudy director
- Government of IndiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.